E.A. GOROKHOVA, A.G. ZHIDYAEVSKY, G.S. GALYAUTDINOV

Kazan State Medical University, Kazan, Russian Federation

Contact details:

Gorokhova E.A. ― postgraduate student of the department of hospital therapy

Address: 49 Butlerov St., Kazan, Russian Federation, 420012, e-mail: doctorkdl@mail.ru

Objective ― to evaluate pain, painless ischemia episodes and life quality of patients with atrial fibrillation to increase the effectiveness of long-term anticoagulant therapy.

Material and methods. 47 patients with a permanent form of non-valvular atrial fibrillation were examined. The study was made of the effect of long-term anticoagulant therapy on episodes of pain and painless myocardial ischemia with the help of Holter monitoring. The «MLHFQ» and «Life Quality of Patients with Arrhythmias» questionnaires were used as tools for measuring life quality.

Results. The study revealed the reduction in episodes of painful ischemia according to Holter monitoring, and improvement in life quality against the background of long-term anticoagulant therapy.

Key words: painless myocardial ischemia, painful myocardial ischemia, atrial fibrillation, anticoagulants, life quality.

REFERENCES

1. Kuznetsova M.V. Pain syndrome with an attack of angina pectoris. Meditsinskiy sovet, 2014, no. 12, pp. 49-53.
2. Russian recommendations “Diagnosis and treatment of stable angina pectoris”, developed by a committee of experts of the All-Russian Scientific Society of Cardiology. Prilozhenie 4 k zhurnalu “Kardiovaskulyarnaya terapiya i profilaktika”, 2008, no. 7 (6), 40 p (in Russ.).
3. Conti C.R., Bavry A.A., Petersen J.W. Silent Ischemia: clinical relevance. Journal of the American College of Cardiology, 2012, no. 59, pp. 435-441.
4. Crawford M.H., Bernstein S.J., Deedwania P.C. et al. ASS/ANA Guidelines for Ambulatory Electrocardiography: Executive Summary and Recommendations. Circulation, 1999, no. 100, pp. 886-893.
5. Aronov D.M., Lupanov V.P. Funktsional’nye proby v kardiologii. 3-e izd., pererab. i dop. [Functional tests in cardiology. 3rd ed., revised and add.]. Moscow: MEDpress-inform, 2007. 328 p.
6. National guidelines for the treatment of ACS without sustained ST elevation on an ECG. Kardiovaskulyarnaya terapiya i profilaktika, 2006, no. 5, appl. 1 (in Russ.).
7. Colilla S., Crow A., Petkun W. et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. The American Journal of Cardiology, 2013, no. 112, pp. 1142-1147.
8. Haim M., Hoshen M., Reges O. et al. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. Journal of the American Heart Association, 2015, no. 4, e001486.
9. Gurevich M.A. Heart rhythm disorders and their correction in chronic heart failure. Rossiyskiy kardiologicheskiy zhurnal, 2005, no. 3, pp. 5-10 (in Russ.).
10. Stalder M., Bachmann F. Aspirin as a platelet antiaggregant: indications and controversies. Therapeutische Umschau, 1987, no. 8, pp. 584-590.
11. Vanhoutte P.M. Platelets, endothelium and blood vessel wall. Experientia, 1988, no. 44 (2), pp. 105-109.
12. Droste C. Pathophysiology of painful and silent myocardial ischemia. Herz, 1987, no. 12 (6), pp. 369-386.
13. Droste S., Meyer-Blankenburg H., Greenlee M.W., Roskamm H. Effect of physical exercise on pain thresholds and plasma beta-endorphins in patients with silent and symptomatic myocardial ischaemia. European Heart Journal, 1988, no. 9 (Suppl N), pp. 25-33.
14. Hikita H., Kurita A., Takase B. et al. Usefulness of plasma beta-endorphin level, pain threshold and autonomic function in assessing silent myocardial ischemia in patients with and without diabetes mellitus. The American journal of cardiology, 1993, no. 72 (2), pp. 140-143.
15. Janne P., Reynaert C., Cassiers L. et al. Psychological determinants of silent myocardial ischaemia. European Heart Journal, 1987, no. 8 (Suppl G), pp. 125-129.
16. Berman D.S., Rozanski A., Knoebel S.B. The detection of silent ischemia: cautions and precautions. Circulation, 1987, no. 75 (1), pp. 101-105.
17. Weiss A.T., Berman D.S., Lew A.S. et al. Transient ischemic dilation of the left ventricle on stress thallium-201 scintigraphy: a marker of severe and extensive coronary artery disease. Journal of the American college of cardiology, 1987, no. 9, pp. 752-759.
18. Vaslyaeva S.N., Lyusov V.A., Tsygankova O.V. et al. Painless myocardial ischemia: pathogenetic and pathophysiological mechanisms. Traditional and metabolic aspects of therapy. Rossiyskiy kardiologicheskiy zhurnal, 2004, no. 4 (48), pp. 74-82 (in Russ.).
19. National guidelines for the treatment of ACS without sustained ST elevation on an ECG. Kardiovaskulyarnaya terapiya i profilaktika, 2006, no. 5, appl. 1 (in Russ.).
20. Diagnostika i lechenie fibrillyatsii predserdiy. Rekomendatsii Rossiyskogo kardiologicheskogo obshchestva, Vserossiyskogo nauchnogo obshchestva spetsialistov po klinicheskoy elektrofiziologii, aritmologii i kardiostimulyatsii i Assotsiatsii serdechno-sosudistykh khirurgov [Diagnosis and treatment of atrial fibrillation. Recommendations of the Russian Cardiological Society, All-Russian Scientific Society of Specialists in Clinical Electrophysiology, Arrhythmology and Cardiac Stimulation, and the Association of Cardiovascular Surgeons]. Moscow, 2012. 100 p.
21. Bjorck S., Palaszewski B., Friberg L., Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke, 2013, no. 44, pp. 3103-3108.
22. Haim M., Hoshen M., Reges O. et al. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. Journal of the American Heart Association, 2015, no. 4, e001486.
23. Gurevich M.A. Heart rhythm disorders and their correction in chronic heart failure. Rossiyskiy kardiologicheskiy zhurnal, 2005, no. 3, pp. 5-10 (in Russ.).
24. Barrios V., Calderon A., Escobar C., de la Figuera M. Patients with atrial fibrillation in a primary care setting: Val-FAAP study. Revista Espanola de Cardiologia (English Edition), 2012, no. 65 (1), pp. 47-53.
25. Barrios V., Escobar C., Calderon A. et al. Use of antithrombotic therapy according to CHA2DS2-VASc score in patients with atrial fibrillation in primary care. Revista Espanola de Cardiologia (English Edition), 2014, no. 67 (2), pp. 150-151.
26. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Annals of Internal Medicine, 2007, no. 146 (12), pp. 857-867.
27. Hsu J.C., Freeman J.V. Underuse of vitamin K antagonist and direct oral anticoagulants for stroke prevention in patients with atrial fibrillation: a contemporary review. Clinical Pharmacology & Therapeutics, 2018, no. 104 (2), pp. 301-310.
28. Baron-Esquivias G., Marin F., Sanmartin Fernandez M. Rivaroxaban in patients with atrial fibrillation: from ROCKET AF to everyday practice. Expert Review of Cardiovascular Therapy, 2017, no. 15 (5), pp. 403-413.
29. Russo V., Rago A., Proietti R. et al. Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence. Therapeutic Advances in Drug Safety, 2017, no. 8 (2), pp. 67-75.
30. Lüderitz B., Jung W. Quality of life in patients with atrial fibrillation. Archives of Internal Medicine, 2000, no. 160, pp. 1749-1757.
31. Makarov L.M., Komolyatova V.N., Kupriyanova O.O. et al. National Russian recommendations on the application of the Holter monitoring method in clinical practice. Rossiyskiy kardiologicheskiy zhurnal, 2014, no. 2 (106), pp. 6-71 (in Russ.).
32. Libis R.A., Prokof’ev A.B., Kots Ya.I. Evaluation of the quality of life in patients with arrhythmias. Kardiologiya, 1998, no. 3, pp. 49-51 (in Russ.).
33. Rector T.S., Kubo S.H., Cohn J.N. Patients’ self-assessment of their congestive heart failure. Part 2: Content, relia bility and validity of a new measure, the Minnesota Living with Heart Failure questionnaire. Heart Failure, 1987, pp. 198-209.
34. Kodama Y. Evalution of myocardial ischemia using Holter monitoring. Fukuoka Igaku Zasshi, 1995, no. 86 (7), pp. 304-316.
35. Watson T., Shantsila E., Lip G.Y. Mechanism of trombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet, 2009, no. 373, pp. 155-166.
36. Zateyshchikov D.A., Zotova I.V., Dankovtseva E.N. Trombozy i antitromboticheskaya terapiya pri aritmiyakh. 2-e izd. [Thrombosis and antithrombotic therapy for arrhythmias. 2nd ed.]. Moscow: Praktika, 2011. 296 p.
37. Bokeriya L.A., Bokeriya O.L., Bazarsadaeva T.S. et al. Characterization of NO-dependent autoregulation of tissue blood flow during atrial idiopathic atrial fibrillation. Annaly aritmologii, 2013, vol. 10, no. 2, pp. 95-101 (in Russ.).
38. Goldman M.E., Pearce L.A., Hartz R.G. et al. Transesophagelechocardiagraphic Transesophagelechocardiagraphic correlates of clinical risk of thromboembolism in non valvular atrial fibrillation. Reduced flow velocity in the left atrial appendage. Journal of the American Society of Echocardiography, 2001, no.12, pp. 1080-1087.
39. Mitusch R., Siemens H.J., Garbe M. et al. Detection of a hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticoagulant therapy. Journal of Thrombosis and Haemostasis, 1996, no. 75, pp. 219-223.
40. Cai H., Li Z., Goette A. et al. Down regulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms of atrial thrombosis and stroke. Circulation, 2002, no. 106 (22), pp. 2854-2858.
41. Sirotin B.Z., Zhmerenetskiy K.V. Mikrotsirkulyatsiya pri serdechno-sosudistykh zabolevaniyakh [Microcirculation in cardiovascular diseases]. Khabarovsk: Dal’nevostochnyy gosudarstvennyy meditsinskiy universitet, 2008. 150 p.
42. Belenkov Yu.N., Shakar’yants G.A., Khabarova N.V. Tactics of selection of anticoagulant therapy in patients with atrial fibrillation and coronary heart disease. Kardiologiya, 2018, no. 58 (3), pp. 43-52 (in Russ.).
43. Kannel W.B., Wolf P.A., Benjamin E.J. et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based stimates. The American journal of cardiology, 1998, no. 82 (8A), pp. 2N-9N.
44. Zolotovskaya I.A., Davydkin I.L., Poverennova I.E., Romanchuk N.P. Effect of anticoagulant therapy on the parameters of arterial stiffness and endothelial dysfunction in patients with atrial fibrillation who have had a cardioembolic stroke. Nevrologiya, neyropsikhiatriya, psikhosomatika, 2016, no. 8 (4), pp. 25-31 (in Russ.).
45. Yoshino S., Yoshikawa A., Hamasaki S. et al. Atrial fibrillation-induced endothelial dysfunction improves after restoration of sinus rhythm. International Journal of Cardiology, 2013, no. 168 (2), pp. 1280-1285.
46. Kim J.B., Joung H.J., Lee J.M. et al. Evaluation of the vascular protective effects of new oral anticoagulants in high-risk patients with atrial fibrillation (PREFER-AF): study protocol for a randomized controlled trial. Trials, 2016, no. 17 (1), p. 422.
47. Álvarez E., Paradela-Dobarro B., Raposeiras-Roubín S. et al. Protective, repairing and fibrinolytic effects of rivaroxaban on vascular endothelium. British Journal of Clinical Pharmacology, 2018, no. 84 (2), pp. 280-291.
48. Barriosa V., Almendro-Deliab M., Facilac L. et al. Rivaroxaban: searching the integral vascular protection. expert review of clinical pharmacology. Expert Review of clinical Pharmacology, 2018, no. 11 (7), pp. 719-728.
49. Pingel S., Tiyerili V., Mueller J. et al. Thrombin inhibition by dabigatran attenuates atherosclerosis in ApoE deficient mice. Archives of Medical Science, 2014, no. 10 (1), pp. 154-160.
50. Zaret B.L., Kayden D.S. Ambulatory monitoring of left ventricular function: a new modality for assessing silent myocardial ischemia. Advances in Cardiology, 1990, no. 37, pp. 105-116.
51. Villari A., Giurdanella G., Bucolo C. et al. Apixaban Enhances Vasodilatation Mediated by Protease-Activated Receptor 2 in Isolated Rat Arteries. Frontiers in Pharmacology, 2017, no. 8, article 480.